A unique characteristic of the hepatitis B virus is the production of a secreted form (precore or HBeAg) of the structural nucleocapsid (core or HBcAg). By using T cell receptor (TCR) transgenic (Tg) and TCR ؋ HBc͞HBeAg double-and triple-Tg pairs, we demonstrate that HBeAg elicits T cell tolerance, whereas HBcAg is nontolerogenic in this system. In fact, TCR ؋ HBc double-Tg mice spontaneously seroconvert to IgG anti-HBc positivity at an early age. However, the presence of HBeAg in the serum of TCR ؋ HBc ؋ HBe triple-Tg mice prevents anti-HBc seroconversion. HBeAg mediates its immunoregulatory effect by eliciting tolerance in HBc͞HBeAg-specific T cells. The results suggest that hepadnaviruses have retained a secretory form of the nucleoprotein because it functions as a T cell tolerogen and regulates the immune response to the intracellular nucleocapsid. This HBeAg-mediated immune regulation may predispose to chronicity during perinatal infections and prevent severe liver injury during adult infections.
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T
he hepatitis E antigen (precore or HBeAg) is secreted into the serum as a monomer, whereas the hepatitis core antigen (HBcAg) is cellular, and its particulate structure encapsidates the viral DNA and polymerase (1) . These two antigenic forms are crossreactive at the T cell level because of extensive amino acid homology but are not crossreactive at the level of antibody recognition. The function of HBeAg has been the subject of speculation since its discovery Ͼ30 years ago (2) because it is not required for viral infection, replication, or assembly (3) (4) (5) . In the past, we have suggested an immunoregulatory role for HBeAg based on murine experimental studies (6, 7) . This issue remains complex because both forms of the nucleoprotein coexist in hepatitis B virus (HBV) natural infection, and the immune responses to HBcAg and HBeAg appear to be regulated independently. For example, HBcAg can behave as a T cell-independent antigen, whereas the immune response to HBeAg is strictly T cell-dependent (8) ; HBcAg preferentially elicits T helper 1 (Th 1 ) cells, and HBeAg preferentially elicits Th 0 ͞Th 2 cells (9); and HBcAg and HBeAg differ in terms of their primary antigen-presenting cells (10) . Adding to the complexity, we have recently demonstrated that a ''split'' tolerance between HBeAg and HBcAg occurs because HBeAg is significantly more tolerogenic for T cells. Furthermore, T cell tolerance to HBeAg is clonal and can be mediated by at least three mechanisms: clonal deletion, clonal anergy, and clonal ignorance (unpublished data). High-avidity T cells are likely to be deleted by serum HBeAg, whereas HBeAg-specific T cells of intermediate avidity may not be deleted but nevertheless can be tolerized by means of clonal anergy. Therefore, even HBeAg-specific T cells of lower avidity are vulnerable to HBeAg-induced tolerance.
The current study is focused on a single HBc͞HBeAg-specific T cell clonal population with an intermediate avidity for the HBc͞ HBeAgs represented by a T cell receptor (TCR) transgenic (Tg) lineage. TCR-Tg mice were bred with HBcAg-and͞or HBeAgexpressing Tg mice to produce double-and triple-Tg pairs. This approach allowed examination of the effect of endogenous HBeAg and HBcAg, both singularly and combined, on a defined HBc͞ HBeAg-specific T cell population. The results unambiguously demonstrate that serum HBeAg can function as an efficient T cell tolerogen and can down-regulate the immune response to HBcAg in a Tg system in which HBcAg is a strong immunogen.
is specific for residues 120-140 of HBc͞HBeAgs, is restricted by the I-A b MHC class II molecule, and is expressed on 53% of CD4 ϩ T cells (unpublished data). Tg mice engineered to express relatively high levels of HBeAg (4-10 g͞ml serum) and HBcAg (0.2-2 g͞mg liver protein) exclusively in the liver through the use of the liver-specific major urinary protein promoter have been described (11, 12) , as has an HBeAg-Tg lineage that expresses a lower level of HBeAg (10 ng͞ml) (13) . All Tg mice were bred onto a C57BL͞10 background. The mice designated as HBcAgor HBeAg-Tg were hemizygous for the transgenes, as were the 7͞16-5 TCR-Tg mice. All animal care was performed according to National Institutes of Health standards as set forth in Guide for the Care and Use of Laboratory Animals (14) .
Recombinant Proteins and Synthetic Peptides. Recombinant HBcAg of the ayw subtype was produced in Escherichia coli and purified as described in ref. 15 . A recombinant HBeAg corresponding in sequence to serum-derived HBeAg encompassing the 10 precore amino acids remaining after cleavage of the precursor and residues 1-149 of HBcAg was produced as described in ref. 16 . The presence of the 10 precore amino acids prevents particle assembly, and HBeAg is recognized efficiently by HBeAgspecific mAbs but displays little HBc antigenicity. Peptides were synthesized by the simultaneous multiple peptide synthesis method (17) . The HBe͞HBcAg-derived synthetic peptide representing the recognition site for the 7͞16-5 TCR was designated by the following amino acid position from the N terminus of HBcAg: 120-140, VSFGVWIRTPPAYRPPNAPIL.
Serology. HBeAg was measured in diluted Tg mouse sera by a commercial ELISA (ETI-EBK PLUS kit, DiaSorin, Stillwater, MN), and rHBeAg was used as a standard. Anti-HBc and -HBe IgG antibodies were measured in murine sera by an indirect solid-phase ELISA with rHBcAg or rHBeAg as the solid-phase ligands as described in ref. 18 . The data are expressed as antibody titers representing the reciprocal of the highest dilution of sera required to yield an optical density at 492 nm (OD 492 ), 3 times an equal dilution of preimmunization sera. IgG isotype-specific ELISAs were performed by using IgG1-, IgG2a-, IgG2b-, and IgG3-specific secondary antibodies (Southern Biotechnology Associates). To detect anti-HBc or -HBe antibodies in culture supernatants, the same ELISAs were used, except that undiluted supernatants were used, and data are reported as OD 492 values.
Liver HBcAg Content. Liver homogenates were prepared in water by using a tissue homogenizer. The tissue lysates were centrifuged at 20,000 ϫ g for 15 min to remove membranes. The total protein content of the water-soluble supernatant was determined by using a Bradford reagent. The concentration of HBcAg in the supernatant was determined by using a modified commercial anti-HBc assay (ETI-AB-COREK PLUS, DiaSorin). The anti-HBc assay was converted to a solid-phase HBcAg capture assay by replacing the rHBcAg-containing neutralization reagent with dilutions of liver supernatant as the source of HBcAg. By using rHBcAg as a standard, the assay was capable of detecting 0.3 ng͞ml HBcAg.
In Vitro Cytokine Analysis. Spleen cells from either unprimed or primed TCR-Tg or -Ag double-or triple-Tg mice were cultured (5 ϫ 10 6 per ml) with concentrations of a series of antigens. Culture supernatants were harvested at 48 h for IL-2 and at 96 h for IFN-␥ determinations. Cytokines were measured by two-site ELISA with pairs of cytokine-specific mAbs. One unlabeled mAb was absorbed to the microtiter plate well and used as a capture antibody, and the other, labeled mAb served as the probe. 6 , which is published as supporting information on the PNAS web site). By breeding triple-Tg mice that express the 7͞16-5 TCR, HBcAg, and HBeAg, we were able to determine whether the immunogenic response to the HBcAg or the tolerogenic response to HBeAg would predominate. The presence of HBeAg in the serum (4-10 g͞ml) prevented spontaneous IgG anti-HBc seroconversion in two of six 7͞16-5 ϫ HBc ϫ HBe triple-Tg mice and severely inhibited IgG anti-HBc production in the remaining four mice (Fig. 1) . The low-level anti-HBc antibody that was produced in the triple-Tg mice was delayed in onset and was IgG-isotype-restricted. Therefore, serum HBeAg can function as an immunoregulatory protein and exert a negative effect on the humoral response to HBcAg in vivo. Furthermore, spleen cells derived from 7͞16-5 ϫ HBc and 7͞16-5 ϫ HBe double-Tg and 7͞16-5 ϫ HBc ϫ HBe triple-Tg mice cultured with HBcAg or HBeAg in vitro revealed that 7͞16-5 ϫ HBc spleen cells produced abundant IgG anti-HBc antibodies in primary spleen cultures, whereas 7͞16-5 ϫ HBe double-Tg spleen cells produced no IgG anti-HBe, and, more importantly, triple-Tg spleen cells produced no IgG anti-HBc ( Fig. 2A) . In vitro IgG antibody production in primary spleen cultures paralleled in vivo IgG anti-HBc͞e production in these strains (Fig. 1) . The absence of in vitro IgG anti-HBe production by 7͞16-5 ϫ HBe double-Tg spleen cells confirms that the inability to detect spontaneous IgG anti-HBe antibodies in vivo was not due to immune complexing or masking of anti-HBe by serum HBeAg. Spleen culture supernatants also were examined for IgM anti-HBc production (Fig. 2B) . Although spleen cells from all 7͞16-5 TCR ϩ double-and triple-Tg mice produce IgM A trivial explanation for the negative effect of HBeAg on anti-HBc seroconversion could be the masking of the detection of anti-HBc antibodies by serum HBeAg. Addition of serum from HBeAg-Tg mice to dilutions of anti-HBc antibodies did not affect detection of the anti-HBc antibodies (Fig. 3A) . A second explanation for the reduced anti-HBc production in 7͞16-5 ϫ HBc ϫ HBe triple-Tg mice could be lower amounts of HBcAg in the livers of mice expressing both transgenes. Although HBc͞HBe double-Tg mice tend to express Ϸ2-fold less intracellular HBcAg than HBc single-Tg mice, the absence of a correlation between anti-HBc seroconversion and the amount of HBcAg in the liver indicates that HBcAg concentration, which ranged from 0.2 to 2.0 g͞mg liver protein, was not a limiting factor for anti-HBc antibody production (Fig. 3B ).
Serum HBeAg Elicits T Cell Tolerance in 7͞16-5 TCR-Tg T Cells.
Because of the high frequency of HBc͞HBeAg-specific T cells in 7͞16-5 TCR-Tg mice (53% of CD4 ϩ ), unprimed splenic T cells cultured with HBc͞HBeAgs in vitro produce significant quantities of IL-2 and IFN-␥ (Fig. 4) . Splenic T cells from 7͞16-5 ϫ HBc double-Tg mice produce equivalent amounts of IL-2 and IFN-␥ as T cells from single TCR-Tg mice when cultured with HBcAg, HBeAg, or the p120-140, which is recognized by 7͞16-5 T cells. This lack of T cell tolerance to HBcAg is consistent with the spontaneous production of IgG anti-HBc antibody in 7͞16-5 ϫ HBc double-Tg mice in vivo. In contrast, splenic T cells from 7͞16-5 ϫ HBe double-Tg mice are significantly tolerant at the T cell level and produce minimal T cell cytokines during in vitro culture with the HBc͞HBeAg panel (Fig. 4) . In addition to reduced cytokine production, T cells from 7͞16-5 ϫ HBe double-Tg mice also demonstrate HBc͞HBeAg-specific proliferation defects relative to T cells from single TCR-Tg mice. Furthermore, the T cell tolerance elicited by serum HBeAg in 7͞16-5 ϫ HBe double-Tg mice is not due to clonal deletion of 7͞16-5 T cells in the thymus or spleen and instead represents a form of in vivo anergy (unpublished data). Examination of T cell cytokine production in 7͞16-5 ϫ HBc ϫ HBe triple-Tg mice revealed that the presence of serum HBeAg induced HBc͞HBeAg-specific tolerance in 7͞16-5 T cells to a degree equivalent to that observed in double-Tg 7͞16-5 ϫ HBe mice (Fig. 4) . Therefore, the negative effect of serum HBeAg on spontaneous anti-HBc seroconversion observed in 7͞16-5 ϫ HBc ϫ HBe triple-Tg mice is mediated at the T cell level by means of the ability of secreted ) from 7͞16-5 TCR-Tg donors into T cell-depleted HBeAg-Tg recipients yielded no anti-HBe antibody production, indicating that serum HBeAg was not immunogenic for 7͞16-5 T cells in this setting (Fig. 5) . Adoptive transfer of an identical number of naive 7͞16-5 donor spleen cells into T cell-depleted HBcAg-Tg recipients resulted in high-titer (1:100,000 endpoint dilution) anti-HBc antibody production comprised of all IgG isotypes in recipient mice within 2-4 weeks. In contrast, adoptive transfer of naive 7͞16-5 donor spleen cells into HBc͞HBeAg double-Tg recipients resulted in minimal anti-HBc antibody production that was 0.2% of that produced in single HBcAg-Tg recipients (Fig. 5) . Therefore, in addition to being nonimmunogenic, serum HBeAg tolerized the transferred 7͞16-5 T cells to the extent that they no longer mediated anti-HBc seroconversion in HBc͞HBeAg-Tg recipients. This result is consistent with the absence of spontaneous anti-HBc seroconversion in 7͞16-5 ϫ HBc ϫ HBe triple-Tg mice (Fig. 1) . The presence of even low levels of serum HBeAg (10 ng͞ml) in HBc͞HBe double-Tg recipient mice also curtailed anti-HBc antibody production after adoptive transfer of 7͞16-5 T cells (Fig. 5) . The inhibitory effect of serum HBeAg on anti-HBc seroconversion is mediated at the T cell level because the transferred 7͞16-5 T cells failed to produce antigen-specific IL-2 in HBe single-Tg and in HBc͞HBe double-Tg recipient splenic cultures as opposed to positive cytokine production in HBc single-Tg recipient spleen cultures (Fig. 6A) . Similarly, in vitro IgG anti-HBc͞e antibody production was detected only in the HBc single-Tg recipient spleen culture. In contrast, all Tg recipient spleen cultures produced IgM anti-HBc. However, elevated IgM anti-HBc was produced in HBc ϫ HBe double-Tg recipient spleen cells. This result is consistent with the elevated levels of in vitro IgM anti-HBc produced by spleen cells derived from 7͞16-5 ϫ HBc ϫ HBe triple-Tg mice (Fig. 6 B and C) .
The preceding experiments were performed by transferring naive 7͞16-5 donor spleen cells. Transfer of preactivated 7͞16-5 donor spleen cells (i.e., cultured with p120 -140) into HBc͞e double-Tg recipients elicited 50-fold more in vivo anti-HBc antibody production (1:10,000 titer) as compared with the transfer of naive spleen cells (Fig. 5) . Therefore, activated 7͞16-5 T cells were less sensitive to tolerance induction by serum HBeAg in the recipient. To determine whether the anergic status of 7͞16-5 T cells present in 7͞16-5 ϫ HBe double-Tg mice was reversible, spleen cells derived from double-Tg donors also were transferred into either HBcAg or HBc͞HBe double-Tg recipients. Transfer into HBc͞HBe double-Tg mice resulted in little or no anti-HBc antibody production, whereas transfer into single HBc-Tg recipients resulted in anti-HBc antibody production (1:10,000 titer) (Fig. 5) . The level of anti-HBc antibody production induced by anergic 7͞16-5 donor T cells transferred into HBc-Tg recipients was 10% of that induced by naive 7͞16-5 donor T cells and of restricted IgG isotype but was nonetheless positive, indicating that the tolerant state of 7͞16-5 T cells exposed to serum HBeAg in vivo can be reversed or at least altered in the absence of the tolerogen (i.e., HBeAg). Because the HBeAg-mediated T cell tolerance in this system is nondeletional and reversible in the absence of the tolerogen (HBeAg), it is best described as in vivo anergy or adaptive tolerance (19) . 
Discussion
The split T cell tolerance between HBeAg and HBcAg and the immunoregulatory function of HBeAg described in this study have important implications for perinatal and adult HBV infection and especially for infection with HBeAg Ϫ mutant viruses, which are becoming an increasing clinical problem (20, 21) . Many common mutations in the precore (22) and core promoter regions (23) of the HBV genome abolish or reduce HBeAg synthesis, respectively. Assuming an immunoregulatory role for HBeAg in natural HBV infection, as suggested by these murine studies, one would predict that infection with precore or core promoter mutant viruses may result in enhanced antiviral immune responses and decreased rates of chronicity. The clinical evidence is largely consistent with this prediction. Neonates infected with HBeAg ϩ wild-type HBV predominantly (90%) become chronically infected, whereas neonates infected with HBeAg Ϫ mutant viruses experience a transient acute infection often accompanied by fulminant hepatitis indicative of an aggressive immune response (24, 25) . Similarly, adult infections with HBeAg Ϫ mutant viruses often correlate with acute fulminant hepatitis (26) (27) (28) . Furthermore, emergence of HBeAg Ϫ mutant viruses during chronic HBV infection can, in some cases, lead to exacerbation of liver injury and a poor prognosis, most notably if the HBeAg Ϫ mutant becomes predominant during periods of high viral load (29, 30) . Therefore, the ability of serum HBeAg to function as a T cell tolerogen and to down-regulate the immune response to HBcAg may result in the moderation of HBcAg-specific liver injury during an acute infection and in the promotion and maintenance of viral persistence during a chronic infection, perhaps explaining the correlation between precore and core promoter region mutations and severe liver disease (20, 21, (24) (25) (26) (27) (28) (29) (30) .
Although the 7͞16-5 TCR lineage represents a single HBeAgspecific T cell clone that is very susceptible to tolerance͞anergy, the potential of serum HBeAg to elicit T cell tolerance through the additional mechanisms of clonal deletion, Fas-mediated apoptosis, and clonal ignorance in two additional TCR-Tg lineages and in HBeAg-Tg mice has been demonstrated previously (refs. 7 and 31 and unpublished data). Therefore, T cell tolerance toward HBeAg is clonal and heterogeneous in terms of mechanisms of induction, and this heterogeneity is likely to be evident even within an individual HBV-infected patient. Because the immunogenic target (HBcAg) and the tolerogen (HBeAg) are both present during a wild-type HBV infection, the balance between tolerized, quiescent, and activated HBc͞ HBeAg-specific T cell clones during various phases (i.e., socalled ''tolerance'' and ''clearance'' phases) of chronic infection is likely to be an important determinant of viral clearance and immune-mediated liver injury. The 7͞16-5 TCR-Tg lineage paired with HBc͞HBe-Tg mice is a particularly useful model because it does not require experimental manipulation (i.e., spontaneous anti-HBc seroconversion); the split tolerance between HBeAg and HBcAg is very apparent; and HBeAg-induced T cell tolerance is mediated by in vivo anergy as opposed to clonal deletion. If 7͞16-5-like T cells exist during a natural chronic HBV infection, they may be susceptible to activation through the reversal of the anergic state. The observation that HBeAgspecific T cell tolerance can be reversible in the absence of the tolerogen (Fig. 5) suggests that antiviral treatments that reduce the HBeAg load as well as the viral load, possibly in combination with HBc͞HBeAg-specific immunization, may be effective in the treatment of chronic HBV infection. Furthermore, this TCR͞Ag double-and triple-Tg model will be useful in screening immunomodulatory drugs for the ability to reverse HBeAg-specific T cell tolerance in vivo. 
